1. Home
  2. STR vs PTGX Comparison

STR vs PTGX Comparison

Compare STR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STR
  • PTGX
  • Stock Information
  • Founded
  • STR 2016
  • PTGX 2006
  • Country
  • STR United States
  • PTGX United States
  • Employees
  • STR N/A
  • PTGX N/A
  • Industry
  • STR Oil & Gas Production
  • PTGX Biotechnology: Pharmaceutical Preparations
  • Sector
  • STR Energy
  • PTGX Health Care
  • Exchange
  • STR Nasdaq
  • PTGX Nasdaq
  • Market Cap
  • STR 1.4B
  • PTGX 3.3B
  • IPO Year
  • STR N/A
  • PTGX 2016
  • Fundamental
  • Price
  • STR $17.90
  • PTGX $55.32
  • Analyst Decision
  • STR Buy
  • PTGX Strong Buy
  • Analyst Count
  • STR 6
  • PTGX 9
  • Target Price
  • STR $25.60
  • PTGX $67.11
  • AVG Volume (30 Days)
  • STR 1.3M
  • PTGX 900.6K
  • Earning Date
  • STR 08-06-2025
  • PTGX 08-05-2025
  • Dividend Yield
  • STR 7.80%
  • PTGX N/A
  • EPS Growth
  • STR N/A
  • PTGX N/A
  • EPS
  • STR 0.52
  • PTGX 0.86
  • Revenue
  • STR $636,538,000.00
  • PTGX $207,801,000.00
  • Revenue This Year
  • STR N/A
  • PTGX N/A
  • Revenue Next Year
  • STR N/A
  • PTGX $53.09
  • P/E Ratio
  • STR $34.48
  • PTGX $63.65
  • Revenue Growth
  • STR 7.18
  • PTGX N/A
  • 52 Week Low
  • STR $14.58
  • PTGX $32.50
  • 52 Week High
  • STR $25.64
  • PTGX $60.60
  • Technical
  • Relative Strength Index (RSI)
  • STR 45.11
  • PTGX 61.17
  • Support Level
  • STR $17.60
  • PTGX $49.38
  • Resistance Level
  • STR $18.77
  • PTGX $51.51
  • Average True Range (ATR)
  • STR 0.50
  • PTGX 2.02
  • MACD
  • STR -0.08
  • PTGX 0.02
  • Stochastic Oscillator
  • STR 40.31
  • PTGX 75.62

About STR Sitio Royalties Corp.

Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.

About PTGX Protagonist Therapeutics Inc.

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.

Share on Social Networks: